Aim: In this study, we aimed to investigate the factors that may have the potential to predict pathological complete response (pCR) with platinum-based neoadjuvant chemotherapy (NAC) in ...non-metastatic muscle-invasive bladder cancer (MIBC).Methods: Our study included 46 patients diagnosed with non-metastatic MIBC, who applied to Dicle University Medical Oncology Clinic between 2016-2019 years and received NAC. Age, gender, ECOG performance score, tumor grade, pathological tumor (pT) stage, clinical lymph node (cN) status, localization of the primary tumor in the bladder, presence of comorbid diseases, renal failure status, hydronephrosis, and NAC regimens were analyzed.Results: Of the total 46 patients included in the study, 42 (81.3%) were male and 4 (8.7%) were female. The median age at diagnosis was 61.5 (34-77) years. In the group of patients aged
Aim: The study aimed to investigate risk factors affecting the transmission of and mortality from COVID-19 in patients diagnosed with a malignant disease. In this context, ABO blood groups, gender, ...age, type of malignant disease, type of anti-tumoral agents, comorbidities and stage were examined.
Materials and Methods: Files of 1,256 patients who presented to our clinic between March and December 2020 were retrospectively reviewed. Patients diagnosed with a malignant disease who became infected with COVID-19 and those who did not were compared with regard to demographic, clinical characteristics and laboratory results (status of having been infected with COVID-19, ABO blood groups).
Results: Of 1256 patients in total, 72 (5.7%) were diagnosed with COVID-19. Median age of cancer patients infected with COVID-19 was 53 years (18-80). The most common types of cancer included gastrointestinal cancer (22.2%), breast cancer (20.8%), genitourinary cancer (20.8%) and lung cancer (16.7%). Of the patients diagnosed with COVID-19, 18.1% (n=13) died. Multivariate analysis identified disease stage as an independent prognostic factor for the risk of mortality HR: 0.07, 95% CI (0.007-0.74), (p=0.02). A comparison of patients who became infected with COVID-19 and those who did not with regard to ABO blood groups (p=0.39) showed no statistically significant differences between the two groups. There was also no correlation between ABO blood groups and the risk of COVID-19-related mortality (p=0.83).
Conclusion: In patients suffering from malignant diseases, the ABO blood type exhibited no correlation with the risk of COVID-19 transmission and mortality. This study determined the presence of metastatic disease as a negative prognostic factor. Patients suffering from a metastatic malignant disease represent a high risk group for COVID-19 and should be treated using all necessary precautions.
OBJECTIVEThe aim of this study was to determine the role of 18F-FDG PET/CT in predicting pathological response among patients diagnosed with local or locally advanced breast cancer and receiving ...neoadjuvant chemotherapy (NAC).
METHODSBasal SUVmax value were analyzed in 212 patients and 142 of these patients had posttreatment SUVmax value. Overall pathological complete response (pCRC) was defined as no evidence of residual invasive cancer in breast (pCRB) and axilla (pCRA). Basal SUVmax value of the breast (SUVmaxBI) and axilla (SUVmaxAI) and change in SUVmax of the breast (ΔSUVmaxB) and axilla (ΔSUVmaxA) were measured. The optimal cutoff value of SUVmax and ΔSUVmax were determined by receiver operating characteristic curve analysis.
RESULTSThe number of patients with pCRB was 85 (40.1%), pCRA was 76 (42.5%) and pCRC was 70 (33%). In the artificial neural network-based analysis the ΔSUVmaxB (100%) was the most important variable for predicting pCRB. ΔSUVmaxA (100%) was the most important variable in estimation of pCRA. When pCRC was evaluated, the highest relation was found with ΔSUVmaxB. When the ΔSUVmaxB cutoff value for pCRB and pCRC accepted as ≤−87.9%, its sensitivity was 82.3 and 82.4%, and specificity was 72.5% and 65.9%, respectively (P < 0.001 and P < 0.001, respectively). When the ΔSUVmaxA cutoff value for pCRA and pCRC accepted as ≤−86.6%, its sensitivity was 94.3 and 97.6%, and specificity was 31.3 and 28.2%, respectively (P = 0.017 and P = 0.024, respectively).
CONCLUSIONAlbeit varies according to the molecular subtypes of the breast cancer during NAC, ΔSUVmax value seems to be the most strong factor associated with pCR.
Purpose
We aim to compare the efficiency and toxicity of three different 5-fluorouracil (5-FU) administration types in 5-FU, leucovorin, and oxaliplatin (FOLFOX) combination treatment for adjuvant ...therapy in colorectal cancer (CRC).
Methods
Five hundred and seventy patients with stage III colorectal carcinoma who received different FOLFOX regimens after curative resection were included. Patients were divided into three groups as FOLFOX-4, modified FOLFOX-6 (mFOLFOX-6), and mFOLFOX-4 for comparison of toxicity and disease-free survival (DFS) and overall survival (OS) times.
Results
Three-year DFS rates for FOLFOX-4, mFOLFOX-6, and mFOLFOX-4 groups were 65%, 72%, and 72%, respectively. Five-year OS rates for FOLFOX-4, mFOLFOX-6, and mFOLFOX-4 groups were 69%, 75%, and 67%, respectively. There was no statistically significant difference between the three treatment groups in terms of DFS and OS (
p
= 0.079, and
p
= 0.147, respectively). Among grade 1–2 adverse events (AE), thrombocytopenia, neuropathy, and stomatitis were more common in the mFOLFOX-6-treated group. The frequency of grade 1–2 nausea and vomiting were similar in mFOLFOX-6 (36.3% and 24%, respectively) and mFOLFOX-4 (32.4% and 24.7%, respectively) groups but were higher than that in the FOLFOX-4 (19.5% and 11.3%, respectively) group. Among the most common grade 3–4 AE, neutropenia (53.4%, 9%, and 13.5%, respectively) and diarrhea (10.5%, 2.2%, and 2.4, respectively) were more common in FOLFOX-4. The rate of anemia and febrile neutropenia was similar in treatment groups (
p
= 0.063, and
p
= 0.210, respectively).
Conclusion
In the adjuvant treatment of stage III CRC patients, three different 5-FU administration types in FOLFOX combination treatment can be used with similar efficiency and manageable toxicity.
In this study, we aimed to investigate the causes of liver test abnormalities in newly diagnosed patients naive to anti-tumoral therapy.
This study included a total of 490 patients with ALT levels > ...5X ULN on liver function tests at the initial presentation to our clinic. Data from 247 (50.4%) patients diagnosed with cancer (cohort A) and 243 (49.6%) patients without cancer (cohort B) were compared with regard to the etiology of liver test abnormalities and the risk factors.
The most common etiological factor in cohort A was presence of liver metastasis (31.2%,
= 77). In the comparison of the two groups with regard to etiological factors; the rates of liver metastasis 31.2% vs 0%, (
< 0.001), drug-induced liver toxicity 30/4% vs 19.8%, (
= 0.007), pancreaticobiliary pathology 21.5% vs 14%, (
= 0.03) and chronic viral hepatitis 14.2% vs 7.4%, (
= 0.02) were higher in the cohort A. The rate of NAFLD was higher in the cohort B 6.9% vs 42.2% (
< 0.001).
In our study, the most common cause of liver test abnormalities was the presence of liver metastasis in cohort A and NAFLD in cohort B.
The aim of this study was to investigate the effect of the body fat mass ratio on survival and prognosis in advanced non-small-cell lung cancer patients.
The study includes 200 patients who were ...diagnosed with advanced non-small-cell lung cancer between 2014 and 2018 and whose body fat mass percentage and body mass index (BMI) were determined using the Tanita Body Composition Analyzer during admission.
All patients had advanced incurable non-small-cell lung cancer (30% had locally advanced disease, 70% were stage IV). In the univariate and multivariate analyses, age, gender, histopathological type, smoking history, comorbidities, weight loss in the last six months and body mass index had no statistically significant effect on survival (p > 0.05). However, the performance status (p = 0.008), metastatic status (p = 0.003) and body fat mass ratio (p = 0.01) were found to have a significant effect on overall survival (OS): the median OS was 16.4 mo, in patients with the BFM ratio ≤ 22% and 29.2 mo, in those with > 22% (p = 0.01).
In this study, it was found that the body fat mass ratio was an important prognostic factor in patients with advanced non-small-cell lung cancer.
Celotno besedilo
Dostopno za:
DOBA, IJS, IZUM, KILJ, NUK, OILJ, PILJ, PNG, SAZU, UILJ, UKNU, UL, UM, UPUK, VSZLJ
7.
Mide Kanseri ve Beslenme KEMEÇ, Zeki; IŞIKDOĞAN, Abdurrahman
Dicle tıp dergisi,
06/2020, Letnik:
47, Številka:
2
Journal Article
Recenzirano
Odprti dostop
Giriş: Ülkemizde Güneydoğu ve Doğu Anadolu bölgelerinde mide kanseri en sık rastlanan kanserler arasında yer almaktadır. Çalışmalarda beslenmenin mide kanser etyolojisinde önemli bir faktör olduğu ...tanımlanmıştır. Bu çalışmada, mide kanserinde diyet alışkanlıklarının etkisi araştırıldı.
Yöntemler: Çalışma Dicle Üniversitesi Tıp Fakültesi Hastanesi’nde 2004-2005 tarihleri arasında onkoloji departmanında yürütüldü. Vaka-kontrollü çalışmada sırasıyla 81 mide kanserli hasta (MCH) , 40 sağlıklı gönüllü birey (Kontrol-1), 40 diğer kanserli hasta (Kontrol-2), 3 ana grup olarak değerlendirildi. Katılımcılara ‘Mide Kanseri Takip Formu’ (MKTF) ve ‘Beslenme Anket Formu’ (BAF) kullanılarak anket uygulandı. Bu anketlerde katılımcıların demografik ve beslenme özellikleri arasındaki ilişki ’Pearson Chi-Square testi’ kullanılarak değerlendirildi.
Bulgu-Sonuç: Üç ana grubun demografik ve beslenme değişkenleri karşılaştırıldı. Farklı sonuçlar bulundu. Bazı değişkenler mide kanseri ile ilişkiliyken, bazıları ilişkisiz bulundu. İleri yaş, erkek cinsiyet, kırsal yaşam, ev hanımı ve çiftçilik meslekleri, sosyokültürel-sosyoekonomik düzey düşüklüğü, kalabalık ailede yaşam, A kan grubu, sebze-meyveden kısıtlı beslenme, kötü ağız hijyeni ve yetersiz diş fırçalama alışkanlığı MCH’larında anlamlı bulundu. MCH’ları et, tuzlanıp-saklanmış et ürünleri, tuzlu peynir, tuzlanmış salamura zeytin, kahve, kırmızı pul biberi, meyve, salata, kuruyemiş gibi besin ve içecek gruplarını az tükettikleri tespit edildi. MCH’larında tandır fırın (ateşte/közde pişmiş) ekmeği ve katı-sıvı yağ tüketimi oldukça anlamlıydı.
Diffuse Cutaneous Melanosis is a rare clinical condition characterized by rapidly acquired skin pigmentation that can occur in the course of advanced metastatic melanoma. A 59 year old patient with ...malign melanoma who developed diffuse cutaneous melanosis in the course of the disease is presented. He had multiple hepatic metastasis, lung metastasis, and multiple bone metastases. After the initiation of chemotherapy, he developed progressively darkening of the entire skin, darkened urine. Four months after the onset of melanosis, the patient died. The prognosis are poor in patients with diffuse cutaneous melanosis associated with malign melanoma.
Educational status and the living environment are closely related to the survival rates of patients with head and neck cancer. In this study we evaluate the effects of educational status and the ...living environment on the survival of patients with head and neck cancer.
Patients with head and neck tumors that show squamous cell histological properties were included in the study. Cases had been followed up in Dicle University Medical Faculty Medical Oncology clinic between January 2006 and June 2013. Data was collected retrospectively from the medical records of the patients. Classical parameters, which are considered to affect the prognosis, such as age, gender, stage, tumor localization and performance status, were investigated, in addition to educational status and the living environment.
The study comprised 171 cases. The rate of metastatic disease was determined to be higher in illiterate patients, when compared to ones with at least an elementary school or higher education (12.7% and 8.1%, respectively; p = 0.012). Similarly, patients living in rural areas showed higher rates of metastatic disease, when compared to those living in cities (16.3% and 8.0%, respectively; p = 0.146). It was determined that the educational status (median overall survival in the cases with elementary school or higher education 21.5 months; in cases that cannot read or write, it is 10.3 months; p = 0.001) and the environment being lived (median overall survival in cases living in cities 17.6 months; in cases living in rural areas it is 9.0 months; p = 0.014) affect survival in the patients with head and neck cancer. In the multivariate analysis; age (>60 vs < 60, OR: 1.94, 95% CI 1.19–3.17, p = 0.008), educational status (cases that cannot read or write vs elementary school or higher, OR: 1.64, 95% CI: 1.03–2.62, p = 0.037) and stage (early stage vs local advanced stage, OR: 3.07, 95% CI: 1.58–5.94, p = 0.01, early stage vs late stage, OR: 3.49, 95% CI: 1.52–8.03, p = 0.003) were determined to be independent prognostic factors.
In addition to the classical prognostic factors, educational status was also determined to be an independent prognostic factor in the squamous cell head and neck cancers, and this fact was especially related with late diagnosis. The prognostic effect of living in rural area was determined by univariate analysis; however it was not determined to be an independent prognostic factor in the multivariate analysis.
Purpose
The optimal chemotherapy regimen for concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) remains unclear. Cisplatin-etoposide regimen related toxicity is high, ...weekly regimens have been investigating. We aimed to compare the efficacy and safety of different concurrent chemotherapy regimens in the context.
Methods
A total of 225 patients with locally advanced, unresectable stage III NSCLC were included. Patients who were treated with weekly docetaxel-platin (DP), paclitaxel-platin (PP) and standard dose etoposide-platin (EP) chemotherapy regimens were selected and divided into groups for the comparison of toxicity, response rate, progression free survival (PFS), and overall survival (OS) times.
Results
There was a statistically significant difference between overall response rate of each treatment groups (DP: 96.1%, PP: 94% and EP: 76.7%,
p
< 0.001). The median PFS time of patients who were treated with DP, PP and EP was 16, 15 and 13.3 months, respectively (
p
= 0.435). The median OS time of patients treated with DP, PP and EP was 19.2, 29.7 and 28.3 months, respectively (
p
< 0.001). The rates of adverse events such as nausea, vomiting, neuropathy and anaphylaxis was similar. Grade 1–2 mucositis or esophagitis, anemia, pneumonitis were significantly higher in PP group than other groups. However, hematologic toxicities were higher in the EP group than other groups.
Conclusions
Compared to the weekly chemotherapy regimens with the standard dose, our study demonstrated similar PFS, but a prolonged OS with the EP regimen. The clinical response rate of weekly regimens was better than the full-dose regimen. Adverse events and toxicity rates were different and depended on the type of chemotherapy regimen used.
PDF
